The Company:
With deep expertise in chemistry, Nuvalent is working to create selective medicines designed with the goal to address the needs of patients with cancer. Nuvalent is an exciting early-stage company, bringing together experienced scientists and industry veterans with a proven track record in drug discovery, oncology drug development, and company building.
The Role:
Reporting to the Head of Analytical Sciences within Technical Operations, the Associate Director, Analytical Sciences has responsibility for the strategic analytical aspects of drug substance and drug product development and manufacturing activities across the relevant Nuvalent CRO and CDMOs for late phase programs. The candidate will interface with the program’s Quality Control, Drug Substance, Drug Product, Quality Assurance, and Regulatory CMC functional representatives.
The Associate Director, Analytical Sciences will drive analytical strategy for late-stage small molecule oncology programs. This role would entail internal and external facing responsibilities as a technical analytical sciences representative on cross-functional CMC teams, guiding analytical aspects of drug substance and drug product process validation including leading specification strategy, method optimization and validation, and review of related PPQ documentation. The Associate Director will help to develop processes for managing products through Stage 3 validation (continued process verification) and post approval change management. The successful candidate will participate in driving global regulatory CMC strategy for FDA and ex-US interactions and submissions through authoring and review of technical and submission documents. In addition, the candidate will lead analytical support for resolution of regulatory submission inquiries and post-approval commitments. The ability to thrive in a virtual environment in support of developing and delivering drug substance (DS) and drug product (DP) for fast-paced late phase clinical development and commercial programs will be critical. The role will include leading the build-out of Nuvalent’s commercial analytical function focused on technical analytical support of commercial supply and lifecycle management.
Responsibilities:
• Define/refine and execute on analytical strategy for a late-stage development candidate.
• Ensure DS and DP method optimization and ICH method validations are consistent with late-phase expectations.
• Participate in the strategic definition and justification of late phase-appropriate and commercial SM, Intermediate, DS, and DP specifications.
• Participate as needed on investigation teams as the analytical SME.
• Author and review analytical-relevant regulatory submission documents.
• Author and review relevant change controls and SOPs.
Competencies Include:
• Excellent organization, communication, and multi-tasking skills
• Exceptional interpersonal skills and experience contributing to productive teams and fostering cross functional relationships
• A strong analytical mind, excellent written/interpersonal communication skills, and the ability to build positive, collaborative, cross-functional working relationships
• Ability to work productively, primarily from home, in a fast-paced, results-driven, highly account-able environment where you can demonstrate initiative and make a clear impact
• Proven track record solving analytical and QC challenges with a focus on small molecules.
Qualifications:
• BS or equivalent in chemistry or related discipline with 10-15 years of relevant industry experience or a PhD in chemistry or related discipline with a minimum of 3-5 years of industry experience
• A strong understanding and knowledge of cGMP/ICH regulations and USP Guidelines with the ability to apply them to analytical DS and DP development and manufacturing is required.
• Expertise in late phase small-molecule Drug Substance and Drug Product analytical support of drug development, and commercial and post-approval changes
• Ability to author and review relevant documentation (methods, protocols, reports) as well as regulatory sections.
• Technical leadership experience with CROs and CDMOs
• Mastery of current ICH guidelines and related industry guidelines and practices
• Excellent organization and multi-tasking skills
Nuvalent provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to religion, race, creed, color, sex, sexual orientation, alienage or citizenship status, national origin, age, marital status, pregnancy, disability, veteran or military status, predisposing genetic characteristics or any other characteristic protected by applicable federal, state or local law.
Nuvalent is aware that many companies are dealing with fraudulent job postings on third-party employment search sites and/or individual(s) or entities claiming to be employees of such companies. Those involved are offering fraudulent employment opportunities to applicants, often asking for sensitive personal and financial information, and using such information for criminal activities.
Please be advised that all legitimate correspondence from a Nuvalent employee will come from "@nuvalent.com" email accounts. Automated system response emails from our Greenhouse applicant tracking system come from a “[email protected]” email address. There are no variations of these email addresses and Nuvalent would not request personal and/or financial information via email. Job opportunities would only be extended after a completed job application is submitted by a candidate and a thorough interview process including 1:1 and/or group interviews via phone, video conferencing and/or in-person.
If you believe you have been contacted by anyone misrepresenting themselves as an employee of Nuvalent, please contact Nuvalent at 857-357-7000. Thank you.
Top Skills
What We Do
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. To learn more, visit www.nuvalent.com.
